Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is aims to:
Alzheimer's disease (AD), also known as senile dementia, is the most common neurodegenerative disorder characterized by progressive decline in cognitive function and behavioral impairment. It is estimated that there are approximately 9.83 million AD patients in China, with an average annual treatment cost of about $19,144 per person, accounting for 1.47% of the national gross domestic product, surpassing the global average. This not only severely affects the quality of life for elderly patients but also imposes a heavy economic and caregiving burden on families and society.
Due to the limitations of AD treatment and the irreversibility of its progression, early detection and intervention have become the focus of AD prevention and control efforts. Increasingly, scholars propose shifting the diagnosis and intervention of AD to the preclinical stage, particularly the mild cognitive impairment (MCI) phase and even earlier stages characterized by subjective cognitive decline (SCD). Cognitive leisure activity, as one of the potentially modifiable factors in the preclinical stage of AD, understanding its impact on cognitive function and the neural circuitry regulation mechanisms in this stage is of significant importance. This knowledge can contribute to the development of early targeted intervention measures, preventing or delaying the onset and progression of AD, and promoting healthy aging.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| People in the stage of preclinical Alzheimer's disease | Observe the cognitive leisure activity levels, cognitive function, and MRI characteristics in patients in the preclinical stage of Alzheimer's Disease |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Relationship of the cognitive leisure activity levels, cognitive function, and MRI characteristics. | Other | The cognitive leisure activity levels, cognitive function, and MRI characteristics in people in the preclinical stage of Alzheimer's Disease (AD). |
| Measure | Description | Time Frame |
|---|---|---|
| Cognitive leisure activity levels | The Chinese version of Cognitive & leisure activity scale will be used. Utilizing the Likert 5-point scale with 16 items, total score ranges from 0 to 80 points,higher scores signify increased cognitive leisure activity levels. An abnormal level is determined if the score is below 25 points. | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Memory | The Chinese version of Auditory Verbal Learning Test will be used. This includes immediate memory, short-term memory, long-term memory, and recognition memory. A higher score indicates better memory performance. | Baseline |
| Verbal fluency |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Older adults in the stage of preclinical AD
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Fayang Lian, MD | Contact | 0591-87557768 | 86 | fjslkyk@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Yuanjiao Yan, PHD | Fujian Provincial Hospital\Shengli clinical medical college of Fujian Medical university | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fujian Provincial Hospital | Recruiting | Fuzhou | Fujian | 350001 | China |
Research data and research-related materials will be available in a repository or online. After completion of the study, relevant data will be provided in the form of a URL or DOI.
After completion of the study, relevant data will be provided in the form of a URL or DOI.
Researchers whose proposed use of the data has been approved
Not provided
Not provided
| ID | Term |
|---|---|
| D060825 | Cognitive Dysfunction |
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D003704 | Dementia |
Not provided
Not provided
Not provided
Not provided
Not provided
The Chinese version of Verbal Fluency Test will be used. A higher score indicates better verbal language performance.
| Baseline |
| Executive function | The Chinese version of Shape Trail Test will be used. The shorter the usage time indicates better executive functioning. | Baseline |
| Visuospatial skills | The Chinese version of Rey-Osterrieth Complex Figure Test will be used. A higher score indicates better visual-spatial structural abilities. | Baseline |
| Naming difficulty | The Chinese version of Boston Naming Test will be used. The total scores range from 0 to 30, a higher score indicates better language functioning. | Baseline |
| Amplitude of Low-Frequency Fluctuations | The rest-state functional MRI of Amplitude of Low-Frequency Fluctuations analysis will be performed to investigate the variations in MRI features across different cognitive leisure activities and levels of cognitive functioning. | Baseline |
| Regional Homogeneity | The rest-state functional MRI of Regional Homogeneity analysis will be performed to investigate the variations in MRI features across different cognitive leisure activities and levels of cognitive functioning. | Baseline |
| Functional Connectivity | The rest-state functional MRI of Functional Connectivity analysis will be performed to investigate the variations in MRI features across different cognitive leisure activities and levels of cognitive functioning. | Baseline |
| General cognitive function | The Chinese version of Montreal Cognitive Assessment will be used.The scale has a total score of 30 points, encompassing eight assessment sections: visual-spatial and executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation. It involves multiple cognitive domains. A higher score indicates better cognitive functioning. | Baseline |
| D001927 |
| Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |